These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Mineralocorticoid receptor activation and mineralocorticoid receptor antagonist treatment in cardiac and renal diseases. Bauersachs J; Jaisser F; Toto R Hypertension; 2015 Feb; 65(2):257-63. PubMed ID: 25368026 [No Abstract] [Full Text] [Related]
5. The renin-angiotensin-aldosterone system in parenchymal kidney disease. Maxwell MH; Weidmann P Adv Nephrol Necker Hosp; 1975; 5():301-32. PubMed ID: 171933 [No Abstract] [Full Text] [Related]
6. [Chronic kidney disease and the aldosterone/mineralocorticoid receptor system]. Nagase M; Fujita T Nihon Jinzo Gakkai Shi; 2010; 52(2):125-31. PubMed ID: 20415233 [No Abstract] [Full Text] [Related]
7. Mechanisms of disease: The role of aldosterone in kidney damage and clinical benefits of its blockade. Del Vecchio L; Procaccio M; Viganò S; Cusi D Nat Clin Pract Nephrol; 2007 Jan; 3(1):42-9. PubMed ID: 17183261 [TBL] [Abstract][Full Text] [Related]
8. [The third factor]. Yoshida H; Mizukoshi H; Araki Y Naika; 1971; 28(1):53-7. PubMed ID: 4935655 [No Abstract] [Full Text] [Related]
9. [Aldosterone and kidney damage: clinical implications]. Del Vecchio L; Sitia S G Ital Nefrol; 2009; 26(3):347-54. PubMed ID: 19554532 [TBL] [Abstract][Full Text] [Related]
10. Adverse cardiorenal effects of aldosterone: is aldosterone antagonism beneficial? Coca SG; Perazella MA Expert Rev Cardiovasc Ther; 2005 May; 3(3):497-512. PubMed ID: 15889977 [TBL] [Abstract][Full Text] [Related]
11. [Aldosterone and kidney diseases: an emergent paradigm with important clinical implications]. Bertocchio JP; Jaisser F Nephrol Ther; 2011 Jun; 7(3):139-47. PubMed ID: 21144811 [TBL] [Abstract][Full Text] [Related]
12. Non-genomic actions of aldosterone: mechanisms and consequences in kidney cells. Boldyreff B; Wehling M Nephrol Dial Transplant; 2003 Sep; 18(9):1693-5. PubMed ID: 12937210 [No Abstract] [Full Text] [Related]
13. The role of aldosterone in the spectrum of cardiovascular and kidney disease risk: introduction. Bakris GL Semin Nephrol; 2014 May; 34(3):245-6. PubMed ID: 25016396 [No Abstract] [Full Text] [Related]
14. The renin-angiotensin-aldosterone system: approaches to cardiac and renal therapy. Otte M; Spier A Compend Contin Educ Vet; 2009 Jan; 31(1):E1-7; quiz E7. PubMed ID: 19241351 [TBL] [Abstract][Full Text] [Related]
15. Sickle cell nephropathy: new insights into its pathophysiology. de Jong PE; Statius van Eps LW Kidney Int; 1985 May; 27(5):711-7. PubMed ID: 3894760 [No Abstract] [Full Text] [Related]
16. [New outlook on aldosterone]. Lada W Pol Tyg Lek; 1993 Jan 18-25; 48(3-4):74-6. PubMed ID: 8361894 [No Abstract] [Full Text] [Related]
17. Clinical study of the cardiac findings in patients on chronic maintenance hemodialysis: the relationship to coronary risk factors. Friedman HS; Shah BN; Kim HG; Bove LA; Del Monte MM; Smith AJ Clin Nephrol; 1981 Aug; 16(2):75-85. PubMed ID: 7261485 [No Abstract] [Full Text] [Related]
18. [Hypertensive heart disease in the patient with chronic kidney disease]. Díez J; Laviades C Nefrologia; 2008; 28(2):135-42. PubMed ID: 18454701 [No Abstract] [Full Text] [Related]
19. Induction of cardiac fibrosis by aldosterone. Lijnen P; Petrov V J Mol Cell Cardiol; 2000 Jun; 32(6):865-79. PubMed ID: 10888242 [TBL] [Abstract][Full Text] [Related]
20. Aldosterone and PAI-1: implications for renal injury. Brown NJ; Vaughan DE; Fogo AB J Nephrol; 2002; 15(3):230-5. PubMed ID: 12113592 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]